Strongbridge Biopharma Plc Received its Third Buy in a Row

By Jason Carr

After Oppenheimer and Cantor Fitzgerald assigned a Buy rating to Strongbridge Biopharma Plc in the last month, the company received another Buy, this time from H.C. Wainwright. Analyst Andrew Fein reiterated a Buy rating on Strongbridge Biopharma Plc (NASDAQ: SBBP) today and set a price target of $18. The company’s shares closed yesterday at $7.60.

According to, Fein is a 4-star analyst with an average return of 8.7% and a 52.7% success rate. Fein covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

Currently, the analyst consensus on Strongbridge Biopharma Plc is Strong Buy and the average price target is $14.67, representing a 93.0% upside.

In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $14 price target.

The company has a one-year high of $9.03 and a one-year low of $3.50. Currently, Strongbridge Biopharma Plc has an average volume of 287.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Strongbridge Biopharma Plc is a global rare disease biopharmaceutical company, which is focused on the development and commercialization of novel therapeutic options. It researches, develops, designs, manufactures, produces, supplies, buys, sells, distributes, imports, exports, promotes and deals in pharmaceutical, active pharmaceutical ingredients and others. The company was founded on May 26, 2015 and is headquartered in Lower Southampton, PA.